Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005
- PMID: 17190630
- DOI: 10.1016/j.jaad.2006.06.006
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005
Abstract
Topical photodynamic therapy (PDT) is used to treat nonmelanoma skin cancers, such as actinic keratoses, Bowen's disease, and basal cell carcinoma (superficial and nodular). This article presents up-to-date, practical, evidence-based recommendations on the use of topical PDT using 5-aminolevulinic acid or methyl aminolevulinate for the treatment (and prevention) of nonmelanoma skin cancers. A systematic literature review was conducted (using MEDLINE), and recommendations were made on the basis of the quality of evidence for efficacy, safety/tolerability, cosmetic outcome, and patient satisfaction/preference. Topical PDT is highly effective in the treatment of actinic keratoses, Bowen's disease, superficial and thin nodular basal cell carcinomas, with cosmesis typically superior to that achieved with existing standard therapies. PDT may also be a means of preventing certain nonmelanoma skin cancers in immunosuppressed patients.
Similar articles
-
Photodynamic therapy for nonmelanoma skin cancers. Current review and update.Mol Immunol. 2003 Jul;39(17-18):1133-6. doi: 10.1016/s0161-5890(03)00083-x. Mol Immunol. 2003. PMID: 12835091 Review.
-
Methyl aminolevulinate-PDT for actinic keratoses and superficial nonmelanoma skin cancers.Skin Therapy Lett. 2009 Jul-Aug;14(6):1-3. Skin Therapy Lett. 2009. PMID: 19609473 Review.
-
Methyl aminolevulinate: actinic keratoses and Bowen's disease.Dermatol Clin. 2007 Jan;25(1):81-7. doi: 10.1016/j.det.2006.09.009. Dermatol Clin. 2007. PMID: 17126745 Review.
-
Photodynamic therapy with violet light and topical 6-aminolaevulinic acid in the treatment of actinic keratosis, Bowen's disease and basal cell carcinoma.J Eur Acad Dermatol Venereol. 2001 Nov;15(6):550-4. doi: 10.1046/j.1468-3083.2001.00333.x. J Eur Acad Dermatol Venereol. 2001. PMID: 11843215 Clinical Trial.
-
Methyl aminolaevulinate-photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer.Br J Dermatol. 2007 May;156(5):793-801. doi: 10.1111/j.1365-2133.2007.07833.x. Epub 2007 Apr 5. Br J Dermatol. 2007. PMID: 17419691 Review.
Cited by
-
[Photodynamic therapy for infectious keratitis].Ophthalmologe. 2012 Feb;109(2):165-70. doi: 10.1007/s00347-011-2511-x. Ophthalmologe. 2012. PMID: 22350551 German.
-
A Novel Photosensitizer 3¹,13¹-phenylhydrazine -Mppa (BPHM) and Its in Vitro Photodynamic Therapy against HeLa Cells.Molecules. 2016 Apr 29;21(5):558. doi: 10.3390/molecules21050558. Molecules. 2016. PMID: 27136527 Free PMC article.
-
Noninvasive fluorescence monitoring of protoporphyrin IX production and clinical outcomes in actinic keratoses following short-contact application of 5-aminolevulinate.J Biomed Opt. 2010 Sep-Oct;15(5):051607. doi: 10.1117/1.3484255. J Biomed Opt. 2010. PMID: 21054081 Free PMC article.
-
Green synthesis of silver nanoparticles via Cynara scolymus leaf extracts: The characterization, anticancer potential with photodynamic therapy in MCF7 cells.PLoS One. 2019 Jun 20;14(6):e0216496. doi: 10.1371/journal.pone.0216496. eCollection 2019. PLoS One. 2019. PMID: 31220110 Free PMC article.
-
Light Fractionation Significantly Increases the Efficacy of Photodynamic Therapy Using BF-200 ALA in Normal Mouse Skin.PLoS One. 2016 Feb 12;11(2):e0148850. doi: 10.1371/journal.pone.0148850. eCollection 2016. PLoS One. 2016. PMID: 26872051 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical